Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025PRNewsWire • 05/08/23
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the INDPRNewsWire • 04/04/23
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture ExchangePRNewsWire • 03/13/23
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/28/23
Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023PRNewsWire • 02/07/23
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price RuleGlobeNewsWire • 01/25/23
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31GlobeNewsWire • 01/24/23
Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day PodcastNewsfile Corp • 01/17/23
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome MeasuresGlobeNewsWire • 01/05/23
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia TelangiectasiaGlobeNewsWire • 12/28/22
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022GlobeNewsWire • 11/07/22
Acasti Announces Voting Results from 2022 Annual and Special Meeting of ShareholdersGlobeNewsWire • 09/29/22
Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day PodcastNewsfile Corp • 09/21/22